Dr. Brandy Heckman-Stoddard received a Doctor of Philosophy degree in Molecular and Cellular Biology at Baylor College of Medicine focusing on the intersection of Rho and IGF signaling in mammary gland development and breast cancer before joining the National Cancer Institute as a Cancer Prevention Fellow. During the fellowship she completed a Master's in Public Health at the Johns Hopkins Bloomberg School of Public Health working with the Institute for Global Tobacco Control and the Evidence-Based Practice Center. During her time at NCI as a fellow, she focused on breast cancer prevention research including preclinical development and early clinical trials.
Dr. Heckman-Stoddard's research focuses on drug development for breast cancer prevention and biomarker development. She is particularly interested in local delivery of agents, alternate dosing strategies, biomarkers of efficacy to reduce the number needed to treat, and targeting of stem cells. She serves as program director for the Early Phase Breast Cancer Prevention Clinical Trials grants portfolio and scientific monitor of early phase breast cancer clinical trials within the NCI Division of Cancer Prevention Early Phase Prevention Consortia. Dr. Heckman-Stoddard is also the NCI lead for an NCI-NIDDK collaboration examining cancer incidence within the Diabetes Prevention Program Outcomes Study a randomized study of metformin, lifestyle intervention, versus placebo.